Marvel Fusion, a Munich-based company specialising in nuclear fusion technologies, announced a capital injection of €50 mn, bringing its total Series B fundraising to €113 mn. The funding includes contributions from Siemens Energy, Swedish investment fund EQT Ventures, and the European Innovation Council (EIC). The investment is intended to support the next phases of industrial development in a context of sustained research on applied nuclear fusion.
Industrial partnership and expansion of technological capacity
Marvel Fusion’s total funding now stands at €385 mn, comprising €170 mn in private capital and €215 mn from public-private partnerships. The company plans to complete the construction of a laser technology centre valued at $150 mn (approximately €139 mn), in cooperation with Colorado State University. This facility will host the technical demonstrators required for future industrial applications. An initial demonstration is scheduled for 2026, though no site has yet been designated for the future production facility.
High-intensity laser fusion technology
The technology under development uses short, high-intensity laser pulses applied to fuel sources derived from hydrogen isotopes. The process aims to induce nuclear fusion by recreating the extreme conditions of temperature and pressure. No definitive timeline has been set for industrial rollout, but the company states it is targeting a first reactor prototype by 2032, in collaboration with Siemens Energy for the design of an integrated plant.
Political orientation and inter-state competition
In Germany, nuclear fusion has recently been the subject of a political agreement between the conservative CDU-CSU and the Social Democratic Party (SPD), currently in talks to form a government. Both parties have committed to enhancing public support for fusion research, with a declared objective of developing the world’s first operational fusion reactor on German soil. France, meanwhile, is pursuing the Iter project, based on magnetic confinement fusion, though it has experienced significant delays: plasma production, initially scheduled for 2025, is now postponed until at least 2033.
Innovation ecosystem and hybrid financing
The Marvel Fusion initiative is part of a broader effort to diversify technological approaches in the field of fusion. Partnerships between industrial players and public or academic institutions reflect a hybrid financing model, necessary in a capital-intensive sector with long development cycles. At this stage, the company has not indicated whether further fundraising phases will be initiated prior to entering a pre-commercial stage.
